← All trials
NCT06512584
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 3, 2024
- Primary completion
- Mar 30, 2026
- Completion date
- Apr 27, 2026
- First posted
- Jul 22, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Huazhong University of Science and TechnologyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.